Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO David P. Schenkein Sells 49,374 Shares

Share on StockTwits

Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO David P. Schenkein sold 49,374 shares of the company’s stock in a transaction on Wednesday, May 23rd. The shares were sold at an average price of $90.40, for a total value of $4,463,409.60. Following the completion of the transaction, the chief executive officer now owns 49,374 shares of the company’s stock, valued at $4,463,409.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Agios Pharmaceuticals stock traded down $0.04 during mid-day trading on Friday, hitting $97.47. The stock had a trading volume of 9,166 shares, compared to its average volume of 355,508. The stock has a market cap of $5.73 billion, a price-to-earnings ratio of -14.50 and a beta of 2.00. Agios Pharmaceuticals Inc has a 12 month low of $50.91 and a 12 month high of $99.82.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.03). The firm had revenue of $8.80 million during the quarter, compared to the consensus estimate of $11.93 million. Agios Pharmaceuticals had a negative net margin of 822.32% and a negative return on equity of 61.70%. Agios Pharmaceuticals’s revenue was down 16.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.56) EPS. research analysts predict that Agios Pharmaceuticals Inc will post -6.24 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in AGIO. Lord Abbett & CO. LLC lifted its stake in Agios Pharmaceuticals by 175.8% in the first quarter. Lord Abbett & CO. LLC now owns 1,044,346 shares of the biopharmaceutical company’s stock valued at $85,407,000 after buying an additional 665,684 shares during the period. Baillie Gifford & Co. acquired a new position in Agios Pharmaceuticals in the first quarter valued at about $47,607,000. BlackRock Inc. lifted its stake in Agios Pharmaceuticals by 14.0% in the first quarter. BlackRock Inc. now owns 3,206,053 shares of the biopharmaceutical company’s stock valued at $262,192,000 after buying an additional 393,336 shares during the period. Point72 Asset Management L.P. lifted its stake in Agios Pharmaceuticals by 343.8% in the first quarter. Point72 Asset Management L.P. now owns 406,090 shares of the biopharmaceutical company’s stock valued at $33,210,000 after buying an additional 314,590 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its stake in Agios Pharmaceuticals by 965.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 345,284 shares of the biopharmaceutical company’s stock valued at $19,740,000 after buying an additional 312,878 shares during the period. 94.22% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts recently commented on the company. BidaskClub lowered Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday. Piper Jaffray Companies reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 4th. Credit Suisse Group set a $95.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 7th. ValuEngine upgraded Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Finally, Citigroup initiated coverage on Agios Pharmaceuticals in a research note on Wednesday, May 23rd. They set a “buy” rating and a $117.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Agios Pharmaceuticals currently has an average rating of “Buy” and an average price target of $95.55.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.